We unlock the therapeutic potential of lipid signaling for fibrotic, metabolic and oncology conditions
ABOUT INNOSPERA PHARMA
Innospera Pharma is a clinical-stage biotech developing lipid-mimetic small molecules to restore dysregulated signaling pathways in fibrotic and chronic diseases.
Our lead asset, ING-006, is in Phase 1 for idiopathic pulmonary fibrosis (IPF), with clinical development substantially de-risked by ​​robust Phase 2 data generated with a known pan-PPAR agonist.​​
ING-006 uniquely combines allosteric peroxisome proliferator-activated receptor (PPAR) modulation with orthosteric agonist activity, restoring PPAR signaling across key cell types implicated in fibrosis.
This approach avoids traditional direct pathway inhibitions, often causing toxicities and tolerability issues and supports a differentiated safety and tolerability profile—a critical unmet need in IPF.
Leadership team
Board of Directors
Pierre Laurin BPharm, MSc
Executive Chairman, COO and co-founder, Innospera
François Ravenelle PhD
President and CEO Innospera
Micheline Beauvais CPA, MBA
Ex-CEO
Inversago Pharma​
Patricia Escoffier PhD
Principal
Seido Capital​
Hélène Moore MBA
Director
Anges Québec​
Denis Garceau BPharm, PhD
Ex-CSO
Bellus Health​
Hubert Sibre LLB
Partner
Miller Thomson​
Maxime Daigle CPA
Board Observer, Director, Investissement Québec
Our lead product: ING-006
Restoring Downregulated Biology in IPF
THERAPEUTIC STRATEGY
IPF is characterized by reduced PPAR expression and activity:
-
driven by TGF-ß-induced transcriptional suppression
-
compounded by a disrupted lipid profile that depletes endogenous PPAR ligands
​
Low PPAR activity
removes a brake on TGF-ß signaling, leading also to an upregulation of GPR84.
​
​
​​
RESTORING PPAR ACTIVITY
ING-006 is designed to restore PPAR activity, whilst having no effect on normal PPAR-active cells.
​​
​
​
​
ING-006 only restores what is lost.
Healthy tissues appear spared—a key driver of the exceptional tolerability and safety profile.
​
​​​​​​​
​​​​​​
​
DE-RISKED CLINICAL DEVELOPMENT
In addition to its allosteric PPAR activity, one of ING-006 metabolites is also an orthosteric PPAR agonist with demonstrated safety and activity in phase 2 clinical trials.
​​
ING-006 presents an excellent toxicology profile with high safety margin, and is well tolerated in healthy volunteers in the on-going phase 1 clinical trial.
​
​
​​​
​​​​​​​​​
Our Pipeline
ING-008 and ING-Series: Expanding the Lipid-Mimetic Platform
Next-generation lipid-mimetics
Analogues of prior clinical and preclinical fatty acid products, designed with differentiated PPAR agonist/modulation, potencies and unique DMPK properties.
Organ- and indication-specific potential
Opportunity to target new tissues and diseases while maintaining the strong safety/tolerability profile of the class.
Pipeline expansion
Multiple candidates under evaluation.
​
​
